Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 6/20 | 0.53 |
| ▸ | MMP2 | P08253 | 6/20 | 0.53 |
| ▸ | MMP9 | P14780 | 6/20 | 0.53 |
| ▸ | MMP13 | P45452 | 6/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | MMP8 | P22894 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MMP3 | P08254 | 5/20 | 0.51 |
| ▸ | MMP7 | P09237 | 5/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31086845 | 0.84 | KDM4E (0.72) | MMP1MMP2MMP9MMP13CA1 | |
| SCHEMBL3210497 | 0.84 | KDM4E (0.72) | MMP1MMP2MMP9MMP13CA1 | |
| SCHEMBL31086909 | 0.79 | CA1 (0.54) | MMP1MMP2MMP9MMP13CA1 | |
| SCHEMBL7413136 | 0.75 | MMP9 (0.53) | MMP1MMP2MMP9MMP13CA1 | |
| SCHEMBL5135614 | 0.75 | CA1 (0.59) | MMP1MMP2MMP9MMP13CA1 | |
| SCHEMBL28606962 | 0.74 | NR3C1 (0.46) | MMP1MMP2MMP9MMP13CA1 | |
| SCHEMBL28606960 | 0.74 | NR3C1 (0.46) | MMP1MMP2MMP9MMP13CA1 | |
| SCHEMBL5663653 | 0.74 | MMP1 (0.55) | MMP1MMP2MMP9MMP13CA1 | |
| SCHEMBL5664360 | 0.74 | MMP1 (0.55) | MMP1MMP2MMP9MMP13CA1 | |
| SCHEMBL3139270 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144730-A1 | COMPOSITION FOR SKIN ANTI-AGING, SKIN BRIGHTENING OR SKIN REVERSE-AGING CONTAINING AMIDE-BASED COMPOUND | AMOREPACIFIC CORPORATION (KR) | 2026-05-28 | — | — | US | claimed |
| US-20260083715-A1 | COMPOSITION FOR ENHANCING IMMUNITY CONTAINING AMIDE-BASED COMPOUND | AMOREPACIFIC CORPORATION (KR) | 2026-03-26 | — | — | US | claimed |
| EP-4692062-A1 | NOVEL AMIDE-BASED COMPOUND AND COMPOSITION COMPRISING SAME | Amorepacific Corporation (KR) | 2026-02-11 | — | — | EP | claimed |
| WO-2024205303-A1 | NOVEL AMIDE-BASED COMPOUND AND COMPOSITION COMPRISING SAME | (주)아모레퍼시픽 | 2024-10-03 | — | — | WO | claimed |
| US-20260144730-A1 | COMPOSITION FOR SKIN ANTI-AGING, SKIN BRIGHTENING OR SKIN REVERSE-AGING CONTAINING AMIDE-BASED COMPOUND | AMOREPACIFIC CORPORATION (KR) | 2026-05-28 | — | — | US | disclosed |
| US-20260083715-A1 | COMPOSITION FOR ENHANCING IMMUNITY CONTAINING AMIDE-BASED COMPOUND | AMOREPACIFIC CORPORATION (KR) | 2026-03-26 | — | — | US | disclosed |
| EP-4692062-A1 | NOVEL AMIDE-BASED COMPOUND AND COMPOSITION COMPRISING SAME | Amorepacific Corporation (KR) | 2026-02-11 | — | — | EP | disclosed |
| WO-2024205303-A1 | NOVEL AMIDE-BASED COMPOUND AND COMPOSITION COMPRISING SAME | (주)아모레퍼시픽 | 2024-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260144730-A1 | COMPOSITION FOR SKIN ANTI-AGING, SKIN BRIGHTENING OR SKIN REVERSE-AGING CONTAINING AMIDE-BASED COMPOUND | TYR, ATG13, ARGLU1 | MMP1 531/4885MMP2 694/4885MMP9 1269/4885 |
| US-20260083715-A1 | COMPOSITION FOR ENHANCING IMMUNITY CONTAINING AMIDE-BASED COMPOUND | ARG1, MSR1, TLR1 | MMP1 2517/4885MMP2 1871/4885MMP9 3692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.